{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-088411","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-08-12T20:40:26+00:00","discovered_at":"2026-08-12T20:41:00.310052+00:00","generated_at":"2026-08-12T20:41:11.683659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Turn Therapeutics Q2 net loss $5.85M; GX-03 Phase 2 interim data positive, expands study","bullets":["Net loss $5.85M (-$0.20/share) vs $1.24M (-$0.05) in Q2 2025; cash $10.3M, runway into Q3 2027.","GX-03 Phase 2 interim: 61.5% vs 8.3% clear/almost clear at Week 4; EASI-75 69.2% vs 25.0% at Week 4.","Expanded Stage 2 to 120-135 patients including lower EASI; no serious adverse events; enrollment on track for Q4 2026.","Appointed former FDA Commissioner Stephen Hahn as Executive Clinical and Regulatory Lead on May 18, 2026.","Plans Phase 2a in hidradenitis suppurativa (~60 patients) targeting first dosing Q2 2027; first peer-reviewed publication May 27, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-088411","json":"https://secwatch.observer/filing/0001213900-26-088411.json","markdown":"https://secwatch.observer/filing/0001213900-26-088411.md","text":"https://secwatch.observer/filing/0001213900-26-088411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026088411/0001213900-26-088411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026088411/ea0301772-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:41:11.683659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}